With 1.04 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.76 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $3.53 whereas the lowest price it dropped to was $3.265. The 52-week range on ATYR shows that it touched its highest point at $3.68 and its lowest point at $1.08 during that stretch. It currently has a 1-year price target of $21.29. Beta for the stock currently stands at 1.06.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of ATYR was up-trending over the past week, with a rise of 10.79%, but this was up by 55.80% over a month. Three-month performance surged to 88.65% while six-month performance rose 91.76%. The stock gained 211.61% in the past year, while it has gained 147.52% so far this year. A look at the trailing 12-month EPS for ATYR yields -0.94 with Next year EPS estimates of -0.81. For the next quarter, that number is -0.23. This implies an EPS growth rate of 2.28% for this year and 11.66% for next year. EPS is expected to grow by 13.00% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of 43.36%.
Float and Shares Shorts:
At present, 83.94 million ATYR shares are outstanding with a float of 81.75 million shares on hand for trading. On 2024-10-15, short shares totaled 1.07 million, which was 140.99999 higher than short shares on 1726185600. In addition to Dr. Sanjay S. Shukla M.D., M.S. as the firm’s President, CEO & Director, Ms. Jill M. Broadfoot serves as its Chief Financial Officer.
Institutional Ownership:
Through their ownership of 0.70265 of ATYR’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2024-06-30, ATYR reported revenue of $0.0 and operating income of -$17315000.0. The EBITDA in the recently reported quarter was -$16932000.0 and diluted EPS was -$0.23.
Analysts Ratings:
In the same way, a target price assigned to a stock can also reveal much about its potential. With ATYR analysts setting a high price target of 35.0 and a low target of 9.0, the average target price over the next 12 months is 21.29. Based on these targets, ATYR could surge 902.87% to reach the target high and rise by 157.88% to reach the target low. Reaching the average price target will result in a growth of 510.03% from current levels.
Analysts have provided yearly estimates in a range of -$0.85401 being high and -$0.96453 being low. For ATYR, this leads to a yearly average estimate of -$0.91429. The surprise factor in the prior quarter was -$0.24. Based on analyst estimates, the high estimate for the next quarter is -$0.24 and the low estimate is -$0.24. The average estimate for the next quarter is thus -$0.24.
